argenx Announces Positive Phase 2 Results for FB102 in Celiac Disease

argenx SE reported positive topline results from its Phase 2 study of FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The study met its primary endpoint, showing a statistically significant and clinically relevant treatment effect compared to placebo in improving intestinal tissue structure during a gluten challenge. The company plans to advance FB102 into Phase 3 development.